EIR Ventures
  • This is Eir Ventures
  • Team
  • Investments
  • Sustainability
  • News
  • Contact
    • Investor Login
    • Download
Select Page
IO Biotech, Inc. Announces Pricing of Initial Public Offering

IO Biotech, Inc. Announces Pricing of Initial Public Offering

by Thomas Rønn | Nov 5, 2021 | Press Releases, Uncategorised

Congratulations to our portfolio company IO Biotech on the successful IPO on NASDAQ. Great achievement for this pioneering company, and a milestone in the development of new pioneering treatments for Cancer patients based on the company’s T-win technology. Read the...

Recent Posts

  • Eir Ventures upscales with Investment Associate
  • Eir Ventures’ first “seedling” Synklino ApS completes oversubscribed DKK 106 million series A round
  • IO Biotech, Inc. Announces Pricing of Initial Public Offering
  • Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer
  • Eir Ventures completes investment in one-carbon Therapeutics. Magnus Persson and Alexander Mata join the board of directors, with Magnus Persson as chairman

Recent Comments

    Get in Touch
    Eir Ventures is located in Stockholm, Sweden, and Copenhagen, Denmark.
    Sweden Office
    Grev Turegatan 27
    SE-114 38 Stockholm
    Sweden
    Denmark Office
    Havnegade 39
    DK-1058 Copenhagen
    Denmark
    Contact us
    info@eirventures.eu
    ©2021 Eir Ventures.